Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Intel is scheduled to report second-quarter results after the closing bell Thursday, with analysts tracked by Visible Alpha unanimously neutral amid questions surrounding the company's foundry ...

Wall Street's biggest bull sees tech and AI driving an 11% stock gain, fueled by strong fundamentals, M&A activity, and ...